Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Contactin-6 is a cell adhesion molecule of the immunoglobulin superfamily, also known as NB-3, encoded by the CNTN6 gene[1][2]. It is a GPI-anchored membrane protein containing six immunoglobulin-like and four fibronectin type III domains. Contactin-6 plays a major role in the development and maintenance of neuronal connectivity, especially in the central nervous system. It governs processes such as axon guidance, neurite outgrowth, synaptogenesis, and cell adhesion. Contactin-6 interacts with various protein partners, notably forming complexes in cis with latrophilin-1 (an adhesion GPCR), and with molecules such as CHL1, Ptpra, and Notch, participating in pathways critical for neuronal survival and apoptosis modulation[1][2]. Genetic studies have associated alterations in Contactin-6 with neurodevelopmental disorders, including autism spectrum disorder and coordination defects. While of significant interest in neuroscience and disease research, Contactin-6 is not an established therapeutic target and has no approved interacting drugs[1][2].
null
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Contactin-6 (CNTN6).